Product manufacturers require proficient oversight and development of clinical and commercial supply chain logistics to guarantee a continuous supply of products to the clinic and the market. DSI offers logistical oversight from the attainment of raw materials to start the process through to distribution of clinical materials to experimental sites for developmental programs and distributors for commercial products.
Image Credit: DS InPharmatics
Strategy, implementation and on-going supply chain assessment assistance
DSI experts in API (Active Pharmaceutical Ingredient) and Drug Product manufacturing can give guidance to companies during all business aspects. This guidance could influence the supply chain, including the planning of production, sourcing raw materials, materials planning, choosing vendors, cost of goods, inventory planning, and supply redundancies and integrity. DSI can prepare firms for launch, helping to bring novel production facilities online and novel goods to market.
Services
- End-to-end supply chain assessment and optimization
- Planning and management of technology transfer
- Selection of vendors
- Vendor audits and management
- Evaluation of cost of goods
- Strategy for inventory and contingency
Advantages
- A supply chain that is fully optimized
- Lower costs throughout the supply chain and to final product
- Enhanced vendor quality, reliability and integrity
- Contingency planning and supply chain redundancy
About DS InPharmatics 
DS InPharmatics (DSI) provides regulatory, technical, and project management consulting services to healthcare product companies that manufacture and/or market pharmaceuticals, biopharmaceuticals, and cellular and gene therapy products.
Since 2007 we have provided our clients with innovative strategies and exceptional quality work products intended to enhance product development, approval, and marketing presence. Whether advocating CMC strategy, directing CMC operations or developing CMC submission content that represent the best interests of emerging biotech, we focus on the critical CMC issues and build programs that enhance development.
In April 2021 we were thrilled to announce that DSI has just become part of ProductLife Group.
French-headquartered ProductLife Group (PLG) is well-known in the Life Sciences market. It has a track record of successfully managing global outsourcing programs and insourcing services for its international client base. The company is on a mission to help transform human health outcomes by optimizing regulatory affairs, safety & vigilance, and quality compliance for life sciences organizations worldwide.
The fit between our two organizations could not be more perfect. We will complement PLG's growing biotech services portfolio. US biotech sponsors recognize DSI as a leader in consulting for go-to-market strategies and RA pre-market consulting. At the same time, PLG has a strong reputation for managing end-to-end outsourcing of regulatory affairs and pharmacovigilance activities worldwide.
Our merger with PLG will harness our combined strengths, offering our clients on both sides of the Atlantic support with their developed drugs approvals and post-approvals compliance, plus advisory services on the best market strategies to deliver a rapid ROI on their development. Together we will offer our clients increased pharmacovigilance capabilities - including a QPPV; pharmacovigilance consulting; and a fully validated safety database - as well as complementary toxicology-related services; RIM/electronic document management services; and support for medical device regulatory requirements.
We see enormous potential in this new chapter for DSI and you, our clients. As a PLG company, we have the opportunity to become part of a global force in life sciences regulatory and compliance solutions and services, and we're incredibly excited to add our momentum to that effort.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.